Contact
searchSearch
HMP Global
Login

Myelodysplastic Syndromes News

News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Novel NLRP3 Inhibitor Ofirnoflast Demonstrates Clinical Activity in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial...
09/14/2026
Oncology
News
Luspatercept Provides Durable Transfusion Independence in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the...
09/14/2026
Oncology
News
Advanced Age Does Not Compromise Azacitidine Outcomes in Higher-Risk Myelodysplastic Syndromes
07/27/2026
Emily Estrada
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective,...
07/27/2026
Oncology
News
Magrolimab Plus Azacitidine Fails to Improve Outcomes in Higher-Risk Myelodysplastic Syndromes
07/22/2026
Stephanie Holland
The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...
The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...
The phase 3 ENHANCE trial...
07/22/2026
Oncology
News
Early Epoetin Alfa Improves Erythroid Response Without Delaying Transfusion Dependence in Lower-Risk Myelodysplastic Syndromes
07/13/2026
Emily Estrada
Results from the phase 3 EPO-PRETAR trial demonstrated that early initiation of epoetin alfa did not delay progression to transfusion dependence in patients with lower-risk myelodysplastic syndromes, although it significantly improved early...
Results from the phase 3 EPO-PRETAR trial demonstrated that early initiation of epoetin alfa did not delay progression to transfusion dependence in patients with lower-risk myelodysplastic syndromes, although it significantly improved early...
Results from the phase 3...
07/13/2026
Oncology
News
Maximum-Dose Luspatercept Produces Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndromes
07/13/2026
Emily Estrada
Results from the phase 3b MAXILUS trial reinforced the efficacy and safety of maximum-dose luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes, producing durable transfusion independence and sustained erythroid...
Results from the phase 3b MAXILUS trial reinforced the efficacy and safety of maximum-dose luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes, producing durable transfusion independence and sustained erythroid...
Results from the phase 3b...
07/13/2026
Oncology
News
Venetoclax-Based Conditioning Regimen Prior to Allo-HSCT for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
06/30/2026
Emily Estrada
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial...
06/30/2026
Oncology
News
Navitoclax Plus Venetoclax and Decitabine Shows Early Activity in High-Risk Myeloid Malignancies
06/30/2026
Emily Estrada
Results from a phase 1 study demonstrated that the addition of navitoclax to venetoclax plus decitabine was safe and showed encouraging preliminary activity among patients with high-risk myeloid malignancies.
Results from a phase 1 study demonstrated that the addition of navitoclax to venetoclax plus decitabine was safe and showed encouraging preliminary activity among patients with high-risk myeloid malignancies.
Results from a phase 1 study...
06/30/2026
Oncology
News
Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/05/2026
Emily Estrada
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study...
06/05/2026
Oncology

Recent News

FDA Approval
FDA Approves and Launches Generic Lanreotide Injection Referencing Somatuline Depot
09/23/2026
Stephanie Holland
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s...
09/23/2026
Oncology
News
NHS-Galleri Trial Finds No Significant Reduction in Stage III or IV Cancer With Multicancer Blood Screening
09/23/2026
Stephanie Holland
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized...
09/23/2026
Oncology
News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use